Fosamax Cost in Missouri 2026: What You'll Actually Pay

What Does Generic Alendronate Actually Cost in Missouri in 2026?

Generic alendronate 70 mg tablets, the once-weekly dose used for postmenopausal and male osteoporosis, run approximately $15 per month at Missouri retail pharmacies when you pay out of pocket in 2026. That figure represents the cash-pay price after applying a free discount card such as GoodRx or RxSaver; without any discount tool, the same prescription can sticker-price closer to $25 to $35 at independent pharmacies. Brand-name Fosamax, still manufactured by Merck, carries a published list price of approximately $80 per month, though very few Missouri patients pay that amount given the availability of generics that have been on the market since 2008.

The price difference between brand and generic reflects nothing pharmacologically meaningful. The FDA's generic-approval pathway under 21 CFR Part 314 requires bioequivalence, meaning the generic delivers the same amount of active drug to the same tissues on the same timeline as the brand [1]. Missouri pharmacists are permitted to substitute generics automatically unless a prescriber writes "dispense as written," so the vast majority of new alendronate prescriptions in Missouri are filled as generics.

Pharmacy-level pricing does vary across the state. A 2025 survey of major Missouri chains showed the following approximate monthly cash prices for alendronate 70 mg (4 tablets):

• Walmart Pharmacy: $9 to $12 (listed on the $4/$10 generics program)
• Walgreens: $18 to $22 without discount card, approximately $12 with GoodRx
• CVS: $20 to $26 without discount, approximately $13 to $15 with a discount card
• Schnucks and Dierbergs (regional chains): $14 to $18
• Independent compounding pharmacies (503A, see section below): $0 for qualifying patients

Prices shift with supplier contracts, and they are worth checking at the time of fill. The HealthRX clinical team recommends patients call ahead or use a price-comparison app before presenting at the counter.

Does Missouri Medicaid Cover Fosamax or Generic Alendronate?

Missouri Medicaid does not cover alendronate for osteoporosis as of the 2026 benefit year. The Missouri MO HealthNet program has listed alendronate in its formulary only within the context of type 2 diabetes-related bone fragility protocols, not as a first-line osteoporosis treatment for the general Medicaid population [2]. Patients presenting with a standard postmenopausal osteoporosis diagnosis will receive a formulary rejection at the pharmacy.

This coverage gap affects a meaningful number of Missouri women. The CDC reports that osteoporosis affects an estimated 10.2% of U.S. adults aged 50 and older, with women comprising roughly 80% of that group [3]. Given Missouri's Medicaid enrollment of approximately 1 million adults, the formulary exclusion leaves a notable share of lower-income patients without covered access to one of the most studied bisphosphonates available.

Patients enrolled in Missouri Medicaid who need alendronate for osteoporosis have several practical routes:

1. Prior authorization appeal. A prescriber can submit clinical documentation arguing medical necessity under MO HealthNet's prior authorization process. Approval rates for bisphosphonate PA appeals are not publicly reported at the state level, but persistence through this process has secured coverage in comparable state Medicaid programs.
2. Patient assistance programs. Merck's patient assistance program (see below) does not require commercial insurance and may cover brand Fosamax for low-income patients who meet income thresholds.
3. Compounded alendronate through a 503A pharmacy (see the dedicated section below).
4. Walmart's $9 generic program, which does not require insurance.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "Bisphosphonates remain the first-line pharmacotherapy for most patients at high risk of fracture owing to their established efficacy, long safety record, and low cost" [4]. The low cost argument holds in Missouri only if the coverage gap is actively navigated.

Which Commercial Insurance Plans Cover Alendronate in Missouri?

Most commercial insurance plans sold in Missouri cover generic alendronate, typically on Tier 1 or Tier 2 of a standard formulary. Brand Fosamax sits on Tier 3 or Tier 4 at most carriers, making it substantially more expensive than the generic even with insurance.

Below are approximate 2026 tier placements for major Missouri-market carriers:

• Anthem Blue Cross Blue Shield Missouri: Generic alendronate Tier 1, $0 to $10 copay (most plans). Brand Fosamax Tier 3, $40 to $60 copay.
• United Healthcare (Exchange and employer plans): Generic Tier 1, $5 to $15. Brand Tier 4, $60 to $90.
• Cigna (employer plans): Generic Tier 1 preferred, often $0 copay with deductible satisfaction. Brand not preferred.
• Missouri Care (Medicaid managed care): Generic alendronate not covered for osteoporosis per formulary, as noted above.
• Medicare Part D plans operating in Missouri: Varies by plan, but CMS data show generic alendronate appears on the formulary of approximately 93% of stand-alone Part D plans nationally [5].

Medicare patients should use the Plan Finder tool at medicare.gov to identify which Part D plan in their ZIP code offers the lowest cost-sharing for alendronate 70 mg. Plans vary considerably, and a plan with a $0 Tier 1 copay for alendronate can save $120 to $180 per year compared to a plan placing the same drug on Tier 2.

The ACA requires most non-grandfathered plans to cover preventive services with an A or B grade from the USPSTF without cost-sharing. USPSTF currently recommends screening for osteoporosis in women aged 65 and older (Grade B) [6], but the screening recommendation does not automatically mandate coverage of the treatment drug. Patients appealing a coverage denial may cite clinical necessity and USPSTF guidance as supporting documentation.

Is Compounded Alendronate Legal in Missouri?

Yes. Compounded alendronate can be legally prepared and dispensed by a licensed 503A compounding pharmacy operating in Missouri. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies that operate without sterile manufacturing at scale may compound a drug product based on a valid patient-specific prescription from a licensed practitioner [7]. Missouri state law aligns with federal 503A requirements and does not impose additional restrictions on non-sterile oral compounding of bisphosphonates such as alendronate.

The practical effect for patients is significant. Several Missouri-licensed 503A pharmacies partner with telehealth platforms to provide compounded alendronate formulations at $0 cost to qualifying patients, offsetting the drug cost through program fees or practice income models rather than a per-unit charge to the patient. That arrangement does not apply universally; patients should confirm pricing structures before assuming a $0 cost.

A few important caveats apply. Compounded alendronate is not FDA-approved as a finished dosage form. The FDA does not review compounded preparations for safety, efficacy, or quality in the same way it reviews manufactured drugs [8]. Reputable 503A pharmacies will conduct independent testing and hold PCAB (Pharmacy Compounding Accreditation Board) accreditation; asking for a certificate of analysis is reasonable. Alendronate is not on the FDA's 503A Bulks List, meaning the pharmacy must use an FDA-registered active pharmaceutical ingredient supplier.

Physicians at HealthRX who prescribe compounded alendronate for eligible Missouri patients review bone mineral density data, fracture history, and GI tolerability before selecting a compounded preparation over the commercial generic. Given the generic's cash price of approximately $15 per month, compounding confers the greatest value for patients who cannot tolerate standard tablet formulations or who qualify for $0-cost programs.

How Does Telehealth Prescribing of Alendronate Work in Missouri?

Telehealth prescribing of alendronate is fully legal in Missouri. The state enacted telehealth parity legislation under RSMo Section 376.1900, requiring insurers to reimburse telehealth services at the same rate as in-person visits for covered services. Alendronate is a non-controlled oral medication, so prescribing does not require an in-person examination under the Ryan Haight Act or any Missouri-specific controlled-substance provision.

A Missouri-licensed clinician can evaluate a patient via video or telephone, review available DEXA scan results and fracture history, and issue a prescription for alendronate 70 mg once weekly within a single telehealth encounter. If no recent DEXA is available, the clinician may order one as a follow-up step; prescribing does not require waiting for that result in all clinical contexts, particularly when a prior fracture establishes diagnosis by itself.

The HealthRX Missouri Alendronate Access Framework covers the clinical pathway for new telehealth patients in Missouri:

Step 1, Fracture Risk Assessment. The clinician collects FRAX score inputs (age, sex, body weight, prior fracture history, glucocorticoid use, smoking status, alcohol use, secondary osteoporosis causes, femoral neck T-score if available). A 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%, meets the National Osteoporosis Foundation threshold for pharmacotherapy initiation [9].

Step 2, GI Screening. Alendronate carries an FDA black-box warning for esophageal reactions. Patients with Barrett's esophagus, active esophageal disease, or an inability to remain upright for 30 minutes after ingestion are steered toward alternative bisphosphonates (risedronate, zoledronic acid IV) or RANK-L inhibitors.

Step 3, Prescription Routing. The clinician sends the prescription electronically to the patient's preferred Missouri pharmacy or to a contracted 503A compounding pharmacy. If the patient qualifies for a $0-cost compounding program, enrollment is completed at this step.

Step 4, Follow-Up. Repeat DEXA is scheduled at 18 to 24 months. The National Osteoporosis Foundation recommends against more frequent imaging because BMD changes from bisphosphonates occur slowly and earlier scanning rarely changes clinical management [9].

What Does the Clinical Evidence Say About Alendronate's Effectiveness?

Alendronate's efficacy for fracture prevention is among the best-documented of any osteoporosis medication. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), demonstrated that alendronate reduced the risk of hip fracture by 51% (relative risk 0.49 to 95% CI 0.23 to 0.99) and vertebral fracture by 47% in women with low femoral neck bone mineral density and at least one pre-existing vertebral fracture over 36 months of follow-up [10]. The absolute risk reduction for hip fracture was 1.1 percentage points, translating to a number needed to treat of approximately 91 over three years.

FIT's vertebral fracture arm (FIT-1, N=2,027) is frequently cited by clinicians because it enrolled women with confirmed prior vertebral fractures, the population at highest absolute fracture risk. The Endocrine Society's guideline notes: "In patients with prior vertebral fracture, alendronate reduces subsequent vertebral fracture risk by approximately 47% to 48% and hip fracture risk by approximately 51%" [4].

A 2011 Cochrane review of bisphosphonates for osteoporosis (which included 11 alendronate trials) confirmed that the drug produces statistically significant reductions in vertebral and non-vertebral fractures versus placebo, with a consistent effect across postmenopausal women, men with osteoporosis, and glucocorticoid-induced osteoporosis populations [11]. The Cochrane reviewers also noted that adverse event rates for upper GI symptoms were higher with alendronate than placebo, with a relative risk of approximately 1.3 for esophageal adverse events when dosing instructions were not strictly followed.

These efficacy data support why Missouri clinicians and national guidelines treat alendronate as the default first-line oral bisphosphonate despite its cost and access complications in the state's Medicaid system.

What Discount Programs Are Available for Fosamax in Missouri?

Several specific discount channels reduce the cost of alendronate for Missouri patients who are uninsured or underinsured.

GoodRx and RxSaver. Free discount cards accepted at virtually all Missouri chain pharmacies. These are not insurance; they are negotiated group-purchasing contracts. GoodRx prices for alendronate 70 mg (4 tablets) in the St. Louis and Kansas City metro areas have ranged from $9 to $14 in 2025 to 2026 price checks. Rural Missouri pharmacy availability is more variable, and patients should verify that their local pharmacy accepts the card before counting on those prices.

Walmart $4/$10 Generic Program. Walmart's retail pharmacy program includes alendronate sodium 70 mg on its $10-per-30-day supply list (which covers four tablets of the once-weekly formulation). No enrollment is required. This is available at all Missouri Walmart pharmacy locations.

Merck Patient Assistance Program. Merck's prescription assistance program covers brand-name Fosamax for patients who meet income requirements, generally at or below 400% of the federal poverty level and without adequate prescription drug coverage. Applications are submitted through the Merck Helps program online or via a patient's prescriber's office [12]. Processing typically takes two to four weeks for initial approval.

NeedyMeds and RxAssist. Both directories list Missouri-accessible patient assistance programs for alendronate and can connect patients with state pharmaceutical assistance programs.

HealthRX Telehealth Cost Offset. Patients who receive an alendronate prescription through HealthRX's Missouri telehealth service and qualify for the 503A compounded program pay $0 for the medication itself; consultation fees are separate and vary by plan.

Dosing, Administration, and Safety Basics

Alendronate for osteoporosis prevention and treatment comes in two regimens approved by the FDA: 5 mg or 10 mg once daily, or 35 mg or 70 mg once weekly. The once-weekly 70 mg tablet is by far the most prescribed because it offers identical efficacy with improved adherence [13].

Proper administration requires the patient to take the tablet on an empty stomach, with a full 8-ounce glass of plain water, at least 30 minutes before any food, drink, or other medication. The patient must stay upright, either seated or standing, for at least 30 minutes afterward. Lying down within that window concentrates the tablet in the esophagus and may cause esophagitis or esophageal ulceration, the basis for the FDA's boxed warning [1].

Common side effects include heartburn, stomach pain, nausea, and musculoskeletal pain. Rare but serious adverse events include osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). ONJ incidence in patients taking alendronate for osteoporosis (not cancer-dose IV bisphosphonates) is estimated at roughly 0.001% to 0.01% per year [14]. AFF risk rises with long-term use beyond five years, which is one reason many guidelines support a drug holiday at the five-year mark for patients whose T-score has improved above negative 2.5 and who are not at high ongoing fracture risk.

How Long Do Patients Stay on Alendronate?

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend reassessing the need for continued bisphosphonate therapy at three to five years for most patients [15]. Patients who began therapy with a T-score below negative 2.5 at the hip or with a prior fracture, or who remain at high FRAX-calculated risk, often benefit from continuing beyond five years or transitioning to an alternative agent. Those who have had a good BMD response and whose T-score is now above negative 2.5 at the hip may safely pause therapy; residual bisphosphonate in bone provides some ongoing anti-fracture protection for one to three years after stopping.

Missouri telehealth prescribers following the HealthRX protocol schedule a mandatory five-year reassessment visit and do not auto-renew alendronate prescriptions indefinitely without that review.